BTK and ovarian carcinoma: A novel oncogenic isoform of BTK with a survival-promoting function is abundantly expressed in breast cancer, ovarian cancer, prostate cancer, and colorectal cancer (Eifert et al., 2013; Guo et al., 2014; Kokabee et al., 2015; Wang et al., 2016; Conconi et al., 2017; Molina-Cerrillo et al., 2017; Campbell et al., 2018; Chen et al., 2018; Lavitrano et al., 2019).